From the Journals News

Trastuzumab Duocarmazine in Previously Treated HER2-Positive Metastatic Breast Cancer

November 8, 2024 By Matthew Stenger 3 min read
Share Share via Email Share on Facebook Share on LinkedIn Share on X

In the phase III TULIP trial reported in the Journal of Clinical Oncology, Turner et al found that the third-generation HER2-targeted antibody-drug conjugate trastuzumab duocarmazine (T-Duo) improved progression-free survival vs physician's choice (PC) of treatment in patients with previously treated advanced or metastatic HER2-positive breast cancer.

Study Details 

In the open-label trial, 437 patients from sites in 11 countries across Europe, Asia, and North America were randomly assigned 2:1 between December 2017 and September 2020 to receive T-Duo at 1.2 mg/kg every 3 weeks (n = 291) or PC of treatment (n = 146) from among lapatinib/capecitabine, trastuzumab/capecitabine, trastuzumab/vinorelbine, or trastuzumab/eribulin. Patients experienced disease progression during or after at least two HER2-targeted therapies or after ado-trastuzumab emtansine (T-DM1). A total of 94% of patients had metastatic disease. A median of three prior HER2-targeted therapies had been administered in the metastatic setting. The primary endpoint was progression-free survival on blinded independent central review.

Progression-Free Survival

Median progression-free survival was 7.0 months (95% confidence interval [CI] = 5.4–7.2 months) in the T-Duo group vs 4.9 months (95% CI = 4.0–5.5 months) in the PC group (hazard ratio [HR] = 0.64, 95% CI = 0.49–0.84, P =.002). Benefit with T-Duo was observed across most predefined subgroups, according to the investigators.

In the initial analysis, median overall survival was 20.4 months (95% CI = 18.0–23.7 months) in the T-Duo group vs 16.3 months (95% CI = 13.4–22.8 months) in the PC group (HR = 0.83, 95% CI = 0.62–1.09, P = .153). Objective response was observed in 27.8% vs 29.5% of patients, with a median duration of response of 15.1 months vs 4.6 months.

Adverse Events

Grade ≥ 3 adverse events occurred in 52.8% of the T-Duo group vs 48.2% of the PC group; the most common events were keratitis (12.2%), conjunctivitis (5.6%), and neutropenia (4.9%) in the T-Duo group and neutropenia (18.2%), decreased neutrophils (6.6%), and palmar-plantar erythrodysesthesia syndrome (3.6%) in the PC group. Ocular toxicity of any grade in the T-Duo group included keratitis (38.2%), conjunctivitis (38.2%), and dry eye (30.2%). Adverse events led to discontinuation of treatment in 35.4% of the T-Duo group vs 5.8% of the PC group. Ocular toxicity led to discontinuation of treatment in 20.8% vs 0% of patients.

The investigators concluded: “Treatment with T-Duo was manageable, but tolerability was affected by prevalent ocular toxicity, leading to a higher discontinuation rate in the T-Duo arm. T-Duo significantly reduced the risk of progression in patients with advanced HER2-positive breast cancer who have progressed during/after ≥ 2 HER2-targeted therapies or after T-DM1.”

Evelyn van den Tweel, PhD, of Byondis B.V., Nijmegen, the Netherlands, is the corresponding author of the Journal of Clinical Oncology article.

Disclosure: The study was supported by Byondis B.V. For full disclosures of the study authors, visit ascopubs.org.

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.